These SLC22A2 gene variant associations confirm results from many previous GWAS identifying SLC22A2 not only as a susceptibility risk factor for CAD (Nikpay et al., 2015; Yeo et al., 2017; Lempiäinen et al., 2018; Van Der Harst and Verweij, 2018; Svishcheva et al., 2019; Shadrina et al., 2020; Aragam et al., 2022), but also as a marker of lipoprotein (a) levels (Mack et al., 2017; Liu et al., 2019; Sinnott-Armstrong et al., 2021), a well-known genetically determined risk factor of CAD (Berg et al., 1979; Tipping et al., 2009; Schatz et al., 2017; Foscolou et al., 2018). The gene discussed is SLC22A2; the disease is coronary artery disorder.